<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105731">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01702662</url>
  </required_header>
  <id_info>
    <org_study_id>METC2012_150, ABR: 40642</org_study_id>
    <nct_id>NCT01702662</nct_id>
  </id_info>
  <brief_title>Photopill Treatment in Healthy Volunteers</brief_title>
  <acronym>Photopill</acronym>
  <official_title>The Assessment of the Photopill Capsule Treatment for Safety and Feasibility in Healthy Volunteers, a Phase 1 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Photo-bio-stimulation by Low Level Light therapy(LLLT) has demonstrated its clinical use in
      chemotherapy/radiotherapy oral mucositis.

      Unpublished study (Melzer, Ben-Yehuda et al. UEGW 2012) with the Photopill (LLLT) capsule
      treatment in mice showed a significant beneficial effect on the endoscopic severity of
      DSS-induced colitis in mice.

      Therefore a phase 1 trial is designed to assess the safety and feasibility of the Photopill
      treatment in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (Mucosal Aspect at 2nd sigmoidoscopy after 7-14 days) as a Measure of Safety and Tolerability</measure>
    <time_frame>During Study period: day 0-14</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Ulcerated Mucosa of Colon</condition>
  <arm_group>
    <arm_group_label>Photopill treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Photopill treatment, 2 minutes per cm rectal mucosa (3cm) 10 times</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photopill treatment</intervention_name>
    <description>2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.</description>
    <arm_group_label>Photopill treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are generally healthy.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Subjects with any known GI related symptoms complaints or GI diseases.

          -  Subjects with cancer or other life threatening diseases or conditions.

          -  Subjects with cardiovascular or pulmonary diseases.

          -  Pregnant women.

          -  Subjects who underwent any colon surgery.

          -  Morbid Obesity (BMI &gt; 40).

          -  Drug abuse or alcoholism.

          -  Bed-ridden patient.

          -  Any rectal therapy.

          -  Participation in current clinical study or clinical study within 30 days    prior to
             the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert D'Haens, Prof.dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam, department of Gastroenterology</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>October 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Hanke Brandse</investigator_full_name>
    <investigator_title>MD, Phd student, executive investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
